Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PASSAGE BIO, INC.

(PASG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PASSAGE BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

10/04/2021 | 07:33am EST

Item 7.01 Regulation FD Disclosure.

On October 4, 2021, Passage Bio, Inc. (the "Company") updated its corporate presentation, in connection with its participation in the Chardan Annual Genetic Medicines Conference.

A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished with this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.                            Description

99.1             Corporate Presentation.
104            Cover Page Interactive Data File (formatted as Inline XBRL).










                                       2

© Edgar Online, source Glimpses

All news about PASSAGE BIO, INC.
11/19Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/09Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference
AQ
11/05Chardan Adjusts Price Target on Passage Bio to $43 From $45, Maintains Buy Rating
MT
11/04Wedbush Adjusts Passage Bio PT to $23 From $25, Maintains Outperform Rating
MT
11/04PASSAGE BIO, INC. Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/04Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business H..
PU
11/04PASSAGE BIO, INC. : Results of Operations and Financial Condition, Regulation FD Disclosur..
AQ
11/04Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
11/04Earnings Flash (PASG) PASSAGE BIO Posts Q3 Loss $-0.87, vs. Street Est of $-0.87
MT
11/04Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business H..
GL
More news
Analyst Recommendations on PASSAGE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -181 M - -
Net cash 2021 186 M - -
P/E ratio 2021 -2,13x
Yield 2021 -
Capitalization 393 M 393 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 74
Free-Float 87,4%
Chart PASSAGE BIO, INC.
Duration : Period :
Passage Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PASSAGE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 7,27 $
Average target price 27,38 $
Spread / Average Target 277%
EPS Revisions
Managers and Directors
Bruce A. Goldsmith President, Chief Executive Officer & Director
Simona King Chief Financial Officer
Maxine Gowen Chairman
Alex Fotopoulos Chief Technical Officer
David Weinstein Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
PASSAGE BIO, INC.-71.57%393
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678